Academic Unit of Diabetes, Endocrinology and Reproduction, University of Sheffield, Sheffield, UK.
Clin Endocrinol (Oxf). 2013 Sep;79(3):305-9. doi: 10.1111/cen.12240. Epub 2013 Jun 13.
Daily recombinant growth hormone (GH) restores normal growth and body composition in GH-deficient children and adults; however, daily injections are inconvenient and can be distressing for some children. On top of this compliance is a problem in up to 75% of children. Developing long-acting GH formulations has proved challenging, and questions remain regarding safety and efficacy. In this review, we focus on the rationale for generating long-acting GH agonists and the technologies being developed to deliver prolonged exposure to GH.
每日重组人生长激素（GH）可恢复 GH 缺乏症儿童和成人的正常生长和身体组成；然而，每日注射对一些儿童来说既不方便又令人痛苦。除此之外，多达 75%的儿童存在依从性问题。开发长效 GH 制剂已被证明具有挑战性，并且关于安全性和有效性的问题仍然存在。在这篇综述中，我们重点介绍了生成长效 GH 激动剂的基本原理以及正在开发的用于提供 GH 长时间暴露的技术。
